Ray Dalio Biotechnology

Bridgewater Associates, LP

$23.8 Billion
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
REGN Regeneron Pharmaceuticals, Inc.	$74.3B	$132 Million 0.56% of portfolio	235,381	Q3 2025 Added 164.33%
HALO Halozyme Therapeutics, Inc.	$9.75B	$35.7 Million 0.15% of portfolio	487,081	Q3 2025 New
EXEL Exelixis, Inc.	$13.4B	$34.8 Million 0.15% of portfolio	842,965	Q3 2025 Added 3,940.09%
CORT Corcept Therapeutics Inc	$8.09B	$25.4 Million 0.11% of portfolio	305,946	Q3 2025 New
BMRN Biomarin Pharmaceutical Inc	$10.2B	$20.3 Million 0.09% of portfolio	375,683	Q3 2025 Added 64.96%
ALNY Alnylam Pharmaceuticals, Inc.	$55.3B	$15.5 Million 0.07% of portfolio	33,911	Q3 2025 New
VRTX Vertex Pharmaceuticals Inc	$111B	$15 Million 0.06% of portfolio	38,324	Q3 2025 Added 11.44%
MDGL Madrigal Pharmaceuticals, Inc.	$9.05B	$12.7 Million 0.05% of portfolio	27,785	Q3 2025 New
TGTX Tg Therapeutics, Inc.	$4.5B	$12.4 Million 0.05% of portfolio	342,149	Q3 2025 New

INCY Incyte Corp	$23.2B	$11.1 Million 0.05% of portfolio	131,284	Q3 2025 Reduced 66.69%
NVO Novo Nordisk A S	$109B	$7.71 Million 0.03% of portfolio	138,947	Q3 2025 New
SRPT Sarepta Therapeutics, Inc.	$1.65B	$6.79 Million 0.03% of portfolio	352,275	Q3 2025 New
UTHR United Therapeutics Corp	$21.2B	$6.73 Million 0.03% of portfolio	16,065	Q3 2025 Reduced 91.77%
HRMY Harmony Biosciences Holdings, Inc.	$2.01B	$5.83 Million 0.02% of portfolio	211,526	Q3 2025 New
MRNA Moderna, Inc.	$9.69B	$5.74 Million 0.02% of portfolio	222,210	Q3 2025 New
ACAD Acadia Pharmaceuticals Inc	$3.89B	$3.48 Million 0.01% of portfolio	163,245	Q3 2025 New
VKTX Viking Therapeutics, Inc.	$3.05B	$3.15 Million 0.01% of portfolio	123,491	Q3 2025 New
BCRX Biocryst Pharmaceuticals Inc	$1.32B	$3.12 Million 0.01% of portfolio	411,503	Q3 2025 New

IONS Ionis Pharmaceuticals Inc	$10.2B	$2.85 Million 0.01% of portfolio	43,578	Q3 2025 New
CVAC Cure Vac N.V.	$990M	$2.51 Million 0.01% of portfolio	466,407	Q3 2025 New
TECH Bio Techne Corp	$2.33B	$2.29 Million 0.01% of portfolio	41,146	Q3 2025 New
ADPT Adaptive Biotechnologies Corp	$2.01B	$2.26 Million 0.01% of portfolio	151,254	Q3 2025 New
NUVL Nuvalent, Inc.	$4.15B	$1.91 Million 0.01% of portfolio	22,057	Q3 2025 New
KRYS Krystal Biotech, Inc.	$5.29B	$1.72 Million 0.01% of portfolio	9,723	Q3 2025 New
ADMA Adma Biologics, Inc.	$3.06B	$883,000 0.0% of portfolio	60,282	Q3 2025 New
PTCT Ptc Therapeutics, Inc.	$5.39B	$732,000 0.0% of portfolio	11,938	Q3 2025 New
PCVX Vaxcyte, Inc.	$2.87B	$427,000 0.0% of portfolio	11,855	Q3 2025 New
LGND Ligand Pharmaceuticals Inc	$3.39B	$228,000 0.0% of portfolio	1,288	Q3 2025 New
AKRO Akero Therapeutics, Inc.	$2.52B	$202,000 0.0% of portfolio	4,256	Q3 2025 New

Shares Options

Ray Dalio

Ray Dalio is the founder and co-chief investment officer of Bridgewater Associates, one of the largest and most successful investment firms in the world. Dalio is known for his expertise in macroeconomic investing and his principles-based approach to decision making. He is also a well-known philanthropist and author.

Track Ray Dalio's portfolio

Track Ray Dalio's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.

Account